메뉴 건너뛰기




Volumn 112, Issue 5-6, 2003, Pages 301-306

Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels

Author keywords

Anti Xa activity; Clotting time; Enoxaparin

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN;

EID: 12144287441     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.01.006     Document Type: Article
Times cited : (13)

References (21)
  • 1
    • 8544279582 scopus 로고    scopus 로고
    • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
    • Cohen M., Demers C., Gurfinkel E.et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 337:1997;447-452.
    • (1997) N. Engl. J. Med. , vol.337 , pp. 447-452
    • Cohen, M.1    Demers, C.2    Gurfinkel, E.3
  • 2
    • 0032870952 scopus 로고    scopus 로고
    • Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
    • Antman E., McCabe C., Gurfinkel E.et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 100:1999;1593-1601.
    • (1999) Circulation , vol.100 , pp. 1593-1601
    • Antman, E.1    McCabe, C.2    Gurfinkel, E.3
  • 3
    • 0035949117 scopus 로고    scopus 로고
    • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
    • The ASSENT-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 358:2001;605-613.
    • (2001) Lancet , vol.358 , pp. 605-613
  • 4
    • 0006590545 scopus 로고    scopus 로고
    • A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
    • Levine M., Gent M., Hirsh J.et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N. Engl. J. Med. 334:1996;677-681.
    • (1996) N. Engl. J. Med. , vol.334 , pp. 677-681
    • Levine, M.1    Gent, M.2    Hirsh, J.3
  • 5
    • 0033539025 scopus 로고    scopus 로고
    • A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
    • Samama M., Cohen A., Darmon J.et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N. Engl. J. Med. 341:1999;793-800.
    • (1999) N. Engl. J. Med. , vol.341 , pp. 793-800
    • Samama, M.1    Cohen, A.2    Darmon, J.3
  • 6
    • 0030992622 scopus 로고    scopus 로고
    • Dose-ranging trial of enoxaparin for unstable angina: Results of TIMI 11A
    • The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J. Am. Coll. Cardiol. 29:1997;1474-1482.
    • (1997) J. Am. Coll. Cardiol. , vol.29 , pp. 1474-1482
  • 7
    • 0141502511 scopus 로고    scopus 로고
    • A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention results of the evaluating enoxaparin clotting times (ELECT) study
    • Moliterno D., Hermiller J., Kereiakes D.et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention results of the evaluating enoxaparin clotting times (ELECT) study. J. Am. Coll. Cardiol. 42:2003;1132-1139.
    • (2003) J. Am. Coll. Cardiol. , vol.42 , pp. 1132-1139
    • Moliterno, D.1    Hermiller, J.2    Kereiakes, D.3
  • 8
    • 1642343966 scopus 로고    scopus 로고
    • Anti-Xa activity relates to outcomes in acute coronary syndromes treated with enoxaparin
    • Montalescot G., Collet J., Payot L.et al. Anti-Xa activity relates to outcomes in acute coronary syndromes treated with enoxaparin. Circulation. 108:2003;IV-501.
    • (2003) Circulation , vol.108 , pp. 501
    • Montalescot, G.1    Collet, J.2    Payot, L.3
  • 9
    • 0036762612 scopus 로고    scopus 로고
    • In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation
    • Linkins L., Julian J., Rischke J., Hirsh J., Weitz J. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb. Res. 107:2002;241-244.
    • (2002) Thromb. Res. , vol.107 , pp. 241-244
    • Linkins, L.1    Julian, J.2    Rischke, J.3    Hirsh, J.4    Weitz, J.5
  • 11
    • 0028020007 scopus 로고
    • Drawing coagulation studies from arterial lines: An integrative literature review
    • Laxon C., Titler M. Drawing coagulation studies from arterial lines: an integrative literature review. Am. J. Crit. Care. 1:1994;16-24.
    • (1994) Am. J. Crit. Care , vol.1 , pp. 16-24
    • Laxon, C.1    Titler, M.2
  • 12
    • 1642287015 scopus 로고    scopus 로고
    • ENOX package insert. http://enoxtest.com/pdfs/enoxpackageinsert.pdf. 2003.
    • (2003) ENOX Package Insert
  • 13
    • 0035125405 scopus 로고    scopus 로고
    • Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
    • Hirsh J., Warkentin T., Shaughnessy S.et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:2001;64S-94S.
    • (2001) Chest , vol.119
    • Hirsh, J.1    Warkentin, T.2    Shaughnessy, S.3
  • 14
    • 0037846473 scopus 로고    scopus 로고
    • Safety and efficacy of low-dose intravenous enoxaparin and glycoprotein IIb/IIIa inhibitor therapy during percutaneous coronary intervention
    • Carnendran L., Borkowski R., Markabawi B., Warner M. Safety and efficacy of low-dose intravenous enoxaparin and glycoprotein IIb/IIIa inhibitor therapy during percutaneous coronary intervention. J. Invasive Cardiol. 15:2003;235-238.
    • (2003) J. Invasive Cardiol. , vol.15 , pp. 235-238
    • Carnendran, L.1    Borkowski, R.2    Markabawi, B.3    Warner, M.4
  • 15
    • 0037021568 scopus 로고    scopus 로고
    • A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention
    • Choussat R., Montalescot G., Collet J.et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J. Am. Coll. Cardiol. 40:2002;1943-1950.
    • (2002) J. Am. Coll. Cardiol. , vol.40 , pp. 1943-1950
    • Choussat, R.1    Montalescot, G.2    Collet, J.3
  • 16
    • 0035814785 scopus 로고    scopus 로고
    • Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
    • Collet J., Montalescot G., Lison L.et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation. 103:2001;658-663.
    • (2001) Circulation , vol.103 , pp. 658-663
    • Collet, J.1    Montalescot, G.2    Lison, L.3
  • 17
    • 0035318112 scopus 로고    scopus 로고
    • Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
    • Kereiakes D., Grines C., Fry E.et al. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invasive Cardiol. 13:2001;272-278.
    • (2001) J. Invasive Cardiol. , vol.13 , pp. 272-278
    • Kereiakes, D.1    Grines, C.2    Fry, E.3
  • 18
    • 18744418112 scopus 로고    scopus 로고
    • Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "nICE guys finish first"
    • Kereiakes D., Fry E., Matthai W.et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first" J. Invasive Cardiol. 12(Suppl. A):2000;1A-5A.
    • (2000) J. Invasive Cardiol. , vol.12 , Issue.SUPPL. A
    • Kereiakes, D.1    Fry, E.2    Matthai, W.3
  • 19
    • 0035097509 scopus 로고    scopus 로고
    • Dalteparin in combination with abciximab during percutaneous coronary intervention
    • Kereiakes D., Kleiman N., Fry E.et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am. Heart J. 141:2001;348-352.
    • (2001) Am. Heart J. , vol.141 , pp. 348-352
    • Kereiakes, D.1    Kleiman, N.2    Fry, E.3
  • 20
    • 0000381222 scopus 로고    scopus 로고
    • Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: The PEPCI Study [abstract]
    • [Suppl.]
    • Martin J., Fry E., Serano A. Pharmacokinetic study of enoxaparin in patients undergoing coronary intervention after treatment with subcutaneous enoxaparin in acute coronary syndromes: the PEPCI Study [abstract]. Eur. Heart J. 22:2001;14. [Suppl.].
    • (2001) Eur. Heart J. , vol.22 , pp. 14
    • Martin, J.1    Fry, E.2    Serano, A.3
  • 21
    • 0032883549 scopus 로고    scopus 로고
    • Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: Inter-assay variability
    • Kitchen S., Iampietro R., Woolley A., Preston F. Anti-Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb. Haemost. 82:1999;1289-1293.
    • (1999) Thromb. Haemost. , vol.82 , pp. 1289-1293
    • Kitchen, S.1    Iampietro, R.2    Woolley, A.3    Preston, F.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.